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Combining radiotherapy with inhibitors of the DNA damage response 
Anthony J Chalmers 
 
Introduction 
Radiotherapy kills cells by damaging DNA and the immediate outcome after radiotherapy (does the 
cell die or survive?) is determined in large part by the ability of the cell to repair the DNA damage 
inflicted by radiation. The fact that radiotherapy is a useful treatment for cancer indicates that, in 
general, the cells of the normal tissues are better equipped to repair DNA damage than their 
malignant counterparts. In line with this general observation, there is increasing evidence that 
abnormalities in the DNA damage response (DDR) are a fundamental characteristic of cancer. This 
evidence base is now sufficiently robust for ‘Genome Instability and Mutation’ to feature as one of 
the two ‘enabling characteristics’ of cancer that were included in Hanahan and Weinberg’s 
‘Hallmarks of Cancer: The Next Generation’ in 2011 [1]. As well as contributing to carcinogenesis and 
malignant progression, DDR defects in cancer represent a promising therapeutic target, most 
famously illustrated by the sensitivity of BRCA-deficient breast and ovarian cancers to drugs that 
inhibit poly(ADP-ribose) polymerase (PARP) [2]. 
The cellular response to DNA damage comprises two main elements: cell cycle checkpoints and DNA 
repair [Figure 1]. Physical and biochemical repair of radiation induced DNA damage is executed by 
three main pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR), 
which repair double stranded DNA breaks (DSB); and base excision repair (BER), which repairs single 
stranded DNA breaks (SSB) (reviewed in [3]). In the context of conventional external beam 
radiotherapy, DSB are generated in far fewer numbers than SSB but are highly mutagenic, and are 
cytotoxic if unrepaired. In contrast, the more numerous SSB are less cytotoxic, less mutagenic and 
more easily repaired. However, unrepaired SSB can be converted to DSB in the context of DNA 
replication and can interfere with important cellular processes such as gene transcription. Both 
pathways play important roles in the day-to-day maintenance of genomic integrity as well as the 
cellular response to genotoxic cancer treatments [4]. 
Cell cycle checkpoints have evolved to protect cells from the potentially catastrophic consequences 
of either replicating damaged DNA or attempting to undergo mitosis while carrying unrepaired DNA 
breaks. Inappropriate DNA replication is prevented by activation of the G1/S checkpoint, governed 
primarily by the ATM/p53/p21 signalling pathway, while entry into mitosis is guarded by the G2/M 
checkpoint under the control of ATM/ATR/Chk1/Chk2/Wee1 signalling. Additional cell cycle 
regulation is provided by intra-S phase and mitotic spindle checkpoints (reviewed in [5]). 
In the context of cancer, defects in DNA repair result in the acquisition and accumulation of 
mutations that can drive carcinogenesis and malignant transformation, while dysfunctional cell cycle 
checkpoints are associated with an increase in the frequency and severity of chromosomal 
aberrations. Loss of cell cycle checkpoint integrity is a critical event in malignant progression: 
oncogenic stress in low grade tumours is associated with constitutive activation of cell cycle 
checkpoint proteins, including ATM, Chk2 and p53, which is significantly reduced in corresponding 
high grade tumours [6]. This somewhat counterintuitive observation led to the hypothesis that 
activated cell cycle checkpoints function as a ‘brake’ on malignant progression of low grade tumours. 
Consistent with this theory, acquisition of ‘loss of function’ mutations in these checkpoint proteins, 
most commonly p53, is associated with malignant progression. While not a universal phenomenon, 
the concept of the DDR as an ‘anti-cancer barrier’ is a plausible explanation for the high prevalence 
of DDR dysfunction in malignant disease, and identifies a family of attractive therapeutic targets 
(reviewed in [7]). 
  Exploiting DDR dysfunction to enhance responses to radiotherapy 
When combining a novel agent with radiotherapy, clinical benefit is only achieved if the therapeutic 
ratio is widened, so it is vital to consider effects on both tumours and normal tissues. In the context 
of radical radiotherapy, radiation dose is limited primarily by the risk of causing irreversible damage 
to adjacent late-responding tissues such as the lung, heart, kidney, bowel, spinal cord or brain. As 
described above, tumour cell DNA damage responses differ from those of late responding normal 
tissues in several ways and thus have potential as tumour specific targets: 
(1) Rapid cellular proliferation, compared with minimal proliferation in late responding tissues 
(2) Elevated oxidative and replication stress 
(3) Loss of function of the G1/S checkpoint and increased dependency on G2/M checkpoint integrity 
(4) Defective DDR resulting from germline or somatic mutations in DDR genes and/or epigenetic or 
post-translational changes. 
In parallel with the advances in cancer biology that revealed these potential targets, a range of 
potent and specific small molecule inhibitors of key DDR proteins have emerged, some of which 
have already entered the clinic. These dual developments make this an exciting and critical time in 
the evolution of individualised radiotherapy.  
 
PARP inhibitors 
Poly(ADP-ribose) polymerase (PARP) is a base excision repair enzyme that, upon sensing and binding 
to SSB, catalyses the addition of long, branching chains of the poly(ADP-ribose) polymer (PAR) to a 
variety of nuclear proteins including histones and other DDR proteins, thus facilitating SSB repair. 
Chemical inhibitors of PARP impede SSB repair and exert potent sensitising effects in combination 
with various cytotoxic drugs including alkylating agents (temozolomide, cyclophosphamide), 
topoisomerase inhibitors (irinotecan, topotecan) and cisplatin. In combination with radiation they 
exert modest sensitising effects on tumour cells but importantly this effect is only observed in 
actively replicating populations [8]. Radiopotentiating effects of PARP inhibitors (PARPi) have been 
demonstrated in vivo in a broad range of preclincial models and in most cases are more pronounced 
than in cellular studies. Together with the absence of radiosensitising effects in non-replicating cells, 
which predicts a lack of effect on late responding normal tissues, and the wealth of favourable 
clinical data for PARPi as single agents, these data have underpinned the emergence of PARPi as the 
first DDR targeting drugs to be tested in combination with radiotherapy in clinical trials. Additional 
mechanisms predicting tumour specificity have also been identified and are reviewed here: [9]. 
Several PARPi are now well characterised in clinical practice as single agents and clinical trials of 
PARPi/radiotherapy combinations are underway (Table 1). Various approaches have been adopted, 
ranging from intensive combinations of PARPi with radical chemoradiation regimes to more 
conservative evaluation of PARPi in combination with lower radiation dose schedules in populations 
of patients who are ineligible for radical treatment. Most combinations are currently undergoing 
phase I testing but the Abbvie PARPi veliparib has successfully progressed to randomised phase II 
evaluation in combination with whole brain radiotherapy for patients with brain metastases from 
non-small cell lung cancer [10].   
 
DNA-PK inhibitors 
Considering its role as a central component of NHEJ, the primary DSB repair pathway in mammalian 
cells, it is not surprising that downregulation of DNA-PK activity either genetically or through 
chemical inhibition is associated with dramatic increases in tumour radiosensitivity [11]. Since NHEJ 
is the only DSB repair pathway that functions during G1 phase of the cell cycle, however, there is a 
significant risk that similar, or even greater, increases in radiosensitivity will be observed in late 
responding normal tissues. Toxicity studies in mice have to date revealed remarkably little evidence 
of this [unpublished data, personal communication], although it should be noted that these 
experiments have only addressed acute toxicity endpoints whereas the late responding normal 
tissues, consisting almost entirely of cells in G0 or G1 phase of the cell cycle, are theoretically at the 
greatest risk. A number of small molecule inhibitors of DNA-PK are in preclinical development and 
the Merck compound MSC2940484A has entered phase I clinical testing in combination with 
radiotherapy in patients receiving palliative radiotherapy for advanced solid tumours. The results of 
this study are eagerly awaited. 
 
Cell cycle checkpoint inhibitors 
The radiopotentiating effects of ATM inhibition are well established, and the potency of these 
compounds is thought to relate to the involvement of ATM in both cell cycle checkpoint activation 
and DNA repair (see Fig 1). Until recently, however, preclinical and clinical development of this class 
of DDRi has been hampered by adverse pharmacokinetic properties. Nonetheless, several research 
groups have demonstrated potent radiosensitising effects of ATM inhibitors including KU-55933 and 
KU-60019 both in vitro and in vivo, with particularly pronounced effects observed in glioblastoma 
(GBM) models [12]. The ability of ATM inhibition to overcome the innate and striking radioresistance 
of GBM stem-like cells has been documented by a number of authors and supports the potential 
therapeutic value of DDR inhibition in this currently incurable cancer [13]. The observation that p53 
wild type cells appear to be relatively unresponsive to ATM inhibition indicates likely tumour 
specificity and also provides opportunities for patient selection [12]. 
Whereas ATM is acknowledged as the prime co-ordinator of the cellular response to radiation 
induced DSB, ATR is generally thought to function predominantly in response to DNA damage 
induced by non-ionising radiation such as ultraviolet light, and in enabling cells to tolerate DNA 
replication stress [5]. This clear division of duties is likely to represent an over-simplification, since 
there is clear evidence of at least partial redundancy between the two proteins, both of which are 
capable of phosphorylating a range of downstream DDR signalling proteins including Chk1, Chk2 and, 
indirectly, Wee1 [14]. In line with this, ATR inhibitors have shown exciting radiosensitising properties 
in a number of different tumour models [15, 16] and in the case of the Vertex compound VE-822 the 
enhancement of tumour growth delay occurred in the absence of any exacerbation of radiation 
damage to the intestine. The AstraZeneca compound AZD6738 is currently undergoing phase I 
evaluation in the context of a novel study design in which the combination with radiotherapy is 
evaluated as part of the First-In-Human study. Many of the functions of ATR are mediated through 
phosphorylation and activation of Chk1, and while Chk1 inhibitors have exhibited promising 
radiosensitising effects in preclinical studies, toxicity issues have hampered their clinical 
development. More recently, inhibition of Wee1, another kinase that promotes G2/M checkpoint 
activation in response to radiation, has emerged as a potential therapeutic strategy [17]. As with 
ATM inhibitors, a number of studies have indicated that the effects of ATR or Wee1 inhibitors are 
more pronounced in p53 defective contexts [18, 19]. 
Summary 
Building on the success of PARP inhibitors as ‘synthetically lethal’ single agents in the treatment of 
HR deficient cancers, combining DDR inhibition with radiotherapy provides exciting opportunities to 
improve clinical outcomes for a much broader spectrum of solid tumours. Emerging data cataloguing 
the extent and patterns of DDR dysfunction that are a key feature of the malignant phenotype will 
facilitate a precision medicine approach in which the most appropriate DDR inhibitor/radiotherapy 
combination can be selected for each patient. Crucially, the preclinical data indicate that the 
radiopotentiating effects of many DDR inhibitors are likely to be tumour specific. Clinical trials are 
now underway that will demonstrate whether this compelling scientific rationale translates into 
clinical benefit. 
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Figure Legends 
Figure 1: 
Highly simplified diagram showing key components of the DDR, their relationships with the cell cycle 
and the sites of action of selected DDR inhibitors. The phases of the cell cycle are represented in 
grey along the central axis of the figure. G1/S, intra-S and G2/M cell cycle checkpoints are illustrated 
by grey symbols, with relative size and colour representing the extent to which tumour cells are 
dependent on their function. The major repair pathways for radiation-induced DNA breaks are 
shown, with SSB repair pathways above and DSB repair pathways below the cell cycle axis. The 
relevance of these cell cycle dependent processes to effects of radiation-drug combinations on 
proliferating tumour cells and non-proliferating cells of late responding normal tissues are indicated 
by the large grey boxes. Tumour specificity of the radiosensitising effects of PARP inhibition is 
generated by the requirement for unrepaired single strand breaks to be converted to double strand 
breaks during DNA replication in S phase. Tumour specificity of inhibitors of ATM, ATR and Wee1 is 
predicted by the primary functions of their major targets taking place within S phase (ATR) and the 
G2/M checkpoint (ATM, ATR, Wee1).   
 DDR 
target Agent Tumour site Venue Phase 
Radiation 
dose 
Additional 
systemic agent Clinical Trial ID Status 
PARP 
Veliparib Brain metastases USA Phase II 30 Gy in 10# No NCT01657799 Completed, results awaited 
Veliparib Locally advanced rectal cancer USA Phase I 45 Gy in 25# Capecitabine NCT01589419 
Completed, well 
tolerated 
Veliparib Glioblastoma USA Phase I 60 Gy in 30# Temozolomide NCT00770471 
Veliparib/temozolomide 
combination not 
tolerated 
Olaparib Oesophagus Elderly patients UK Phase I 50 Gy in 25# No NCT01460888 Recruiting 
Olaparib Head & neck cancer USA Phase I 69.3 Gy in 33# 
Cetuximab 
250 mg/m2 
weekly 
NCT01758731 Recruiting 
Olaparib Inoperable breast cancer Netherlands Phase I 61.8 Gy in 23# No NCT02227082 Recruiting 
Olaparib Head & neck cancer UK Phase I 70 Gy in 35# 
Cisplatin 
35 mg/m2 
weekly 
NCT02308072 Recruiting 
Olaparib Glioblastoma Elderly patients UK Phase I 40 Gy in 15# No UKCRN18137 Recruiting 
ATR AZD6738 Solid tumours UK Phase I 20 Gy in 5# 30 Gy in 10# No NCT02223923 Recruiting 
DNA-PK MSC2490484A Solid tumours USA, Germany Phase I 
10-25 Gy, 1# 
30 Gy in 10# 
60 Gy in 30# 
No NCT02516813 Recruiting 
Wee1 
MK-1775* Glioblastoma USA Phase I 60 Gy in 30# Temozolomide NCT01849146 Recruiting 
AZD1775* Cervix Canada Phase I 25# then brachytherapy Cisplatin weekly NCT01958658 Recruiting 
 
Table 1: Selected clinical trials evaluating DDR inhibitors in combination with radiotherapy. *Same agent. 
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